Premium
Clinicians in 25 countries prefer to use lower levels of oxygen to resuscitate preterm infants at birth
Author(s) -
Oei Ju Lee,
Ghadge Alpana,
Coates Elisabeth,
Wright Ian M.,
Saugstad Ola D.,
Vento Maximo,
Buonocore Giuseppe,
Nagashima Tatsuo,
Suzuki Keiji,
Hosono Shiguhero,
Davis Peter G.,
Craven Paul,
Askie Lisa,
Dawson Jennifer,
Garg Shalabh,
Keech Anthony,
Rabi Yacov,
Smyth John,
Sinha Sunil,
Stenson Ben,
Lui Kei,
Hunter Carol Lu,
Tarnow Mordi William
Publication year - 2016
Publication title -
acta paediatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/apa.13485
Subject(s) - medicine , percentile , neonatology , resuscitation , pediatrics , neonatal resuscitation , clinical trial , gestation , emergency medicine , pregnancy , statistics , genetics , mathematics , biology
Aim This study determined current international clinical practice and opinions regarding initial fractional inspired oxygen (FiO 2 ) and pulse oximetry (SpO 2 ) targets for delivery room resuscitation of preterm infants of less than 29 weeks of gestation. Methods An online survey was disseminated to neonatal clinicians via established professional clinical networks using a web‐based survey programme between March 9 and June 30, 2015. Results Of the 630 responses from 25 countries, 60% were from neonatologists. The majority (77%) would target SpO 2 between the 10th to 50th percentiles values for full‐term infants. The median starting FiO 2 was 0.3, with Japan using the highest (0.4) and the UK using the lowest (0.21). New Zealand targeted the highest SpO 2 percentiles (median 50%). Most respondents agreed or did not disagree that a trial was required that compared the higher FiO 2 of 0.6 (83%), targeting the 50th SpO 2 percentile (60%), and the lower FiO 2 of 0.21 (80%), targeting the 10th SpO 2 percentile (78%). Most (65%) would join this trial. Many considered that evidence was lacking and further research was needed. Conclusion Clinicians currently favour lower SpO 2 targets for preterm resuscitation, despite acknowledging the lack of evidence for benefit or harm, and 65% would join a clinical trial.